[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371363-105":59,"doc-detail-371363-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","multimodal-diagnostic-models-and-subtype-analysis-for-neoadjuvant-therapy-in-breast-cancer","Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer","","Breast cancer is a heterogeneous malignancy with multiple molecular subtypes, making prediction of neoadjuvant therapy (NAT) efficacy difficult. This study integrates proteomic, genomic, MRI imaging, and clinical data from multiple cohorts, then applies Lasso regression for feature extraction and selection. Five machine learning models evaluate pathological complete response (pCR) as the endpoint. Results show a multi-omics Ridge regression model with AUC 0.917 and reveal four NAT-associated multimodal subtypes with distinct molecular and immune microenvironment characteristics. Single-cell and cell-cell communication analyses support subtype-specific tumor heterogeneity and differential interaction patterns.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multimodal-diagnostic-models-and-subtype-analysis-for-neoadjuvant-therapy-in-breast-cancer/371363/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multimodal-diagnostic-models-and-subtype-analysis-for-neoadjuvant-therapy-in-breast-cancer/371363.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of this research on breast cancer?","Question",{"text":113,"@type":114},"The research aims to build multimodal diagnostic models and perform subtype analysis to predict the efficacy of neoadjuvant therapy in breast cancer, using pathological complete response (pCR) as the predictive endpoint.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which data types and cohorts are integrated in the study?",{"text":118,"@type":114},"The study integrates proteomic, genomic, MRI imaging, and clinical information from multiple cohorts, including I-SPY2, TCGA-BRCA, GSE161529, and METABRIC.",{"name":120,"@type":111,"acceptedAnswer":121},"How were diagnostic features selected and models constructed?",{"text":122,"@type":114},"After preprocessing the data, Lasso regression was used for feature extraction and selection, and five machine learning algorithms were then used to construct diagnostic models.",{"name":124,"@type":111,"acceptedAnswer":125},"What key findings were reported about NAT-associated subtypes?",{"text":126,"@type":114},"Unsupervised clustering identified four distinct multimodal breast cancer subtypes associated with NAT, showing significant differences in proteomic profiles, pathway activities, tumor immune microenvironments, transcription factor activities, and clinical characteristics.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},371363,1790319098,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","TYPE Original Research PUBLISHED 18 March 2025  \nDOI 10.3389/fimmu.2025.1559200  \nOPEN ACCESS  \nEDITED BY  \nEkene Emmanuel Nweke,  \nUniversity of the Witwatersrand, South Africa  \nREVIEWED BY  \nJunwei Han,  \nHarbin Medical University, China Tanya Nadine Augustine,  \nUniversity of the Witwatersrand, South Africa Kutlwano Xulu,  \nUniversity of the Witwatersrand, South Africa  \n*CORRESPONDENCE  \nPeng Xu  \n [gdxupeng@gzhu.edu.cn](gdxupeng@gzhu.edu.cn)[ ](gdxupeng@gzhu.edu.cn)Wenbin Liu  \n [wbliu6910@gzhu.edu.cn](wbliu6910@gzhu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 12 January 2025  \nACCEPTED 26 February 2025  \nPUBLISHED 18 March 2025  \nCITATION  \nYe Z, Yuan J, Hong D, Xu P and Liu W (2025) Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer.  \nFront. Immunol. 16:1559200 .  \ndoi: 10.3389/fimmu.2025.1559200  \nCOPYRIGHT  \n© 2025 Ye, Yuan, Hong, Xu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMultimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer  \nZheng Ye 1,2†, Jiaqi Yuan 1†, Deqing Hong 1, Peng Xu 1,2* and Wenbin Liu 1*  \n1 Institute of Computational Science and Technology, Guangzhou University, Guangzhou, China, 2School of Computer Science of Information Technology, Qiannan Normal University for Nationalities, Duyun, Guizhou, China  \nBackground: Breast cancer, a heterogeneous malignancy, comprises multiple subtypes and poses a substantial threat to women's health globally. Neoadjuvant therapy (NAT), administered prior to surgery, is integral to breast cancer treatment strategies. It aims to downsize tumors, optimize surgical outcomes, and evaluate tumor responsiveness to treatment. However, accurately predicting NAT efﬁcacy remains challenging due to the disease's complexity and the diverse responses across different molecular subtypes.  \nMethods: In this study, we harnessed multimodal data, including proteomic, genomic, MRI imaging, and clinical information, sourced from multiple cohorts such as I-SPY2, TCGA-BRCA, GSE161529, and METABRIC . Post data preprocessing, Lasso regression was utilized for feature extraction and selection. Five machine learning algorithms were employed to construct diagnostic models, with pathological complete response (pCR) as the predictive endpoint.  \nResults: Our results revealed that the multi-omics Ridge regression model achieved the optimal performance in predicting pCR, with an AUC of 0 .917. Through unsupervised clustering using the R package MOVICS and nine clustering algorithms, we identiﬁed four distinct multimodal breast cancer subtypes associated with NAT. These subtypes exhibited signiﬁcant differences in proteomic proﬁles, hallmark cancer gene sets, pathway activities, tumor immune microenvironments, transcription factor activities, and clinical characteristics. For instance, CS1 subtype, predominantly ER-positive, had a low pCR rate and poor response to chemotherapy drugs, while CS4 subtype, characterized by high immune inﬁltration, showed a better response to immunotherapy. At the single-cell level, we detected signiﬁcant heterogeneity in the tumor microenvironment among the four subtypes. Malignant cells indifferent subtypes displayed distinct copy number variations, differentiation levels, and evolutionary trajectories. Cell-cell communication analysis further highlighted differential interaction patterns among the subtypes, with implications for tumor progression and treatment response.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: Our m","cbCaimd17wRINULN","https://ap.wps.com/l/cbCaimd17wRINULN","pdf",17840640,31,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main goal of this research on breast cancer?\",\"answer\":\"The research aims to build multimodal diagnostic models and perform subtype analysis to predict the efficacy of neoadjuvant therapy in breast cancer, using pathological complete response (pCR) as the predictive endpoint.\"},{\"question\":\"Which data types and cohorts are integrated in the study?\",\"answer\":\"The study integrates proteomic, genomic, MRI imaging, and clinical information from multiple cohorts, including I-SPY2, TCGA-BRCA, GSE161529, and METABRIC.\"},{\"question\":\"How were diagnostic features selected and models constructed?\",\"answer\":\"After preprocessing the data, Lasso regression was used for feature extraction and selection, and five machine learning algorithms were then used to construct diagnostic models.\"},{\"question\":\"What key findings were reported about NAT-associated subtypes?\",\"answer\":\"Unsupervised clustering identified four distinct multimodal breast cancer subtypes associated with NAT, showing significant differences in proteomic profiles, pathway activities, tumor immune microenvironments, transcription factor activities, and clinical characteristics.\"}]","Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer | PDF",1790191903,78,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acb9f3a0580370db160cb8bb7996a9d4.webp",983,1389,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf68c299208da20f00bee25fd414c88d.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5570fc56bdba3782ee6207877fc1436.webp",981,1386,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c4112d243cbf6cafa6a448c44bff3e3.webp",980,1385]